V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10425811 | 10041485 | 1.49 | 94 | Palliative (P) | 2021-10-19 | 2021-10-24 | MPT | null | null | EVEROLIMUS | 100147381 |
| 10425889 | 10041486 | 1.77 | 82.4 | Palliative (P) | null | 2018-09-01 | FLUOROURACIL + OXALIPLATIN | 01 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100869305 |
| 10425915 | 10041487 | 1.81 | 64.4 | Palliative (P) | 2017-11-06 | 2017-11-06 | Ipilimumab | 02 | N | CISPLATIN + ETOPOSIDE | 100585376 |
| 10426008 | 10041491 | 1.6 | 84.6 | null | 2016-09-09 | 2018-08-25 | CRIZOTINIB | null | N | CISPLATIN + ETOPOSIDE | 100681031 |
| 10426012 | 10041492 | 1.67 | 46 | Curative (C) | 2019-07-24 | 2019-08-20 | Apalutamide | 2 | null | FEC | 101368666 |
| 10426029 | 10041493 | 1.65 | 61.6 | Disease modification (D) | null | 2018-11-25 | ROMICAR Trial | 02 | Y | BORTEZOMIB + PANOBINOSTAT | 101147227 |
| 10426072 | 10041495 | 1.83 | 72.9 | 03 | 2018-07-15 | 2018-07-15 | CARBOPLATIN + FLUOROURACIL | 02 | N | BENDAMUSTINE | 101453215 |
| 10426086 | 10041496 | null | null | null | 2022-05-15 | 2022-05-23 | Fulvestrant + Palbociclib | 02 | null | TIVOZANIB | 100860858 |
| 10426091 | 10041497 | 1.63 | 54.8 | Palliative (P) | null | 2019-03-10 | Melphalan IV High dose | N | null | PACLITAXEL + TRASTUZUMAB | 100935122 |
| 10426107 | 10041499 | 1.82 | 69.1 | Adjuvant (A) | 2019-08-20 | 2019-08-30 | Bortezomib + MELPHALAN | N | null | CISPLATIN + PEMETREXED | 100900217 |
| 10426111 | 10041500 | 1.71 | 66.4 | 03 | 2019-08-13 | 2019-08-21 | CHLVPP | null | null | OSIMERTINIB | 100438363 |
| 10426113 | 10041501 | 0 | 70 | Curative (C) | 2020-09-15 | 2020-09-30 | Letrozole + Palbociclib | 02 | N | MELPHALAN + THALIDOMIDE | 100372524 |
| 10426284 | 10041502 | 1.62 | 84.2 | 03 | 2021-04-26 | 2021-04-26 | FCR Oral - Cycle 1 | null | null | NILOTINIB | 101252521 |
| 10426516 | 10041506 | 1.69 | 72 | 03 | null | 2020-04-15 | CAPECITABINE + TEMOZOLOMIDE | null | N | CABOZANTINIB | 101003483 |
| 10426519 | 10041507 | 1.63 | null | 03 | 2019-04-04 | 2019-04-11 | AML 19 TRIAL | 02 | N | UKALL60+ | 100611995 |
| 10426523 | 10041508 | 1.54 | 76.5 | 03 | 2018-05-16 | 2018-05-31 | ESHAP R | 02 | N | FLAG + IDARUBICIN | 100706425 |
| 10426583 | 10041509 | 1.5 | 78.5 | Palliative (P) | 2018-09-18 | 2018-09-25 | PRISM TRIAL | 02 | N | ERLOTINIB | 100263884 |
| 10426726 | 10041511 | 1.48 | 101 | 03 | null | 2019-10-30 | Arsenic Triox + Tretinoin Ind W1-4 | 01 | null | CISPLATIN + RT | 101855539 |
| 10426758 | 10041513 | 1.58 | 52.8 | Palliative (P) | 2017-08-20 | 2017-08-22 | null | 02 | N | BLEOMYCIN | 101581227 |
| 10426776 | 10041514 | 1.76 | 102 | Curative (C) | 2017-08-07 | 2017-08-11 | AML 19 TRIAL | Y | null | CAPECITABINE + RT | 101449159 |
| 10426962 | 10041516 | 1.63 | 77.2 | Adjuvant (A) | null | 2019-06-16 | TCH (21 day Trastuzumab) Maint | N | N | APALUTAMIDE | 100865963 |
| 10426982 | 10041517 | null | null | null | 2019-02-25 | 2019-03-09 | IDELALISIB + RITUXIMAB | 02 | null | THALIDOMIDE | 100019271 |
| 10427069 | 10041520 | 1.53 | 61.1 | Curative (C) | 2018-04-19 | 2018-04-22 | null | N | N | PERTUZUMAB + TRASTUZUMAB | 100499022 |
| 10427081 | 10041521 | 1.61 | 60 | Curative (C) | null | 2020-12-16 | null | null | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE | 101356277 |
| 10427178 | 10041522 | 1.75 | null | Palliative (P) | 2019-01-23 | 2019-01-28 | ECF | 02 | N | TRASTUZUMAB | 101754237 |
| 10427335 | 10041525 | null | null | Palliative (P) | 2018-03-20 | 2018-04-04 | Sorafenib | 02 | null | GEFITINIB | 101641676 |
| 10427505 | 10041528 | 1.75 | 68.25 | Disease modification (D) | 2020-10-12 | 2020-10-12 | Epirubicin | N | null | CVD | 100477650 |
| 10427754 | 10041529 | 1.71 | 116.7 | 03 | 2019-04-15 | 2019-04-16 | FLUOROURACIL + IRINOTECAN | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 101263695 |
| 10427838 | 10041530 | 1.82 | 83.6 | Disease modification (D) | 2018-06-17 | 2018-06-25 | DABRAFENIB | 02 | null | CHOP | 100875392 |
| 10427854 | 10041531 | 1.69 | 83 | Palliative (P) | 2018-09-08 | 2018-09-15 | IDELALISIB + RITUXIMAB | 02 | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 101579997 |
| 10427912 | 10041533 | 1.84 | 0 | null | 2019-04-04 | 2019-04-04 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101121211 |
| 10427946 | 10041534 | 1.67 | 85.3 | 03 | 2021-03-30 | 2021-04-11 | Ipilimumab | 02 | N | ANTI-THYMOCYTE GLOBULIN + CYCLOPHOSPHAMIDE | 101224004 |
| 10427984 | 10041535 | 1.65 | null | Curative (C) | 2019-07-18 | 2019-07-26 | VINORELBINE | 02 | N | ABEMACICLIB | 100060850 |
| 10428217 | 10041536 | 1.73 | 73 | 03 | 2016-11-21 | 2016-12-05 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101181031 |
| 10428231 | 10041537 | 1.77 | 83.5 | Disease modification (D) | 2021-06-22 | 2021-06-27 | AC | 02 | null | STAMPEDE TRIAL | 101621534 |
| 10428374 | 10041541 | 1.71 | 80 | null | 2020-04-13 | 2020-04-13 | Atezolizumab | 02 | null | CAPECITABINE + CARBOPLATIN | 100174207 |
| 10428434 | 10041543 | 1.73 | 81 | 03 | 2017-04-15 | 2017-04-26 | CAPECITABINE + CARBOPLATIN | 02 | N | NILOTINIB | 101451403 |
| 10428479 | 10041544 | 1.85 | 72 | Palliative (P) | 2016-12-27 | 2017-01-27 | ECX | null | null | AVELUMAB + AXITINIB | 101214293 |
| 10428531 | 10041545 | 0 | 63.8 | Curative (C) | 2019-08-30 | 2019-09-11 | Fulvestrant + Palbociclib | 02 | null | CYTARABINE + DAUNORUBICIN | 101455148 |
| 10428532 | 10041546 | 1.7 | 53 | Disease modification (D) | 2019-08-07 | 2019-08-07 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | CISPLATIN + PEMETREXED | 101107614 |
| 10428617 | 10041548 | 1.7 | 73 | Adjuvant (A) | 2020-05-10 | 2020-05-10 | BMT Fludarabine/Cyclophosphamide/Alemtuzumab | 02 | null | BORTEZOMIB + MELPHALAN | 100631787 |
| 10428679 | 10041549 | 1.63 | 61.6 | Palliative (P) | 2019-11-29 | 2019-11-29 | Irinotecan + Modified De Gramont | 02 | N | BLEOMYCIN | 101572724 |
| 10428755 | 10041552 | 1.78 | 68 | null | 2019-01-25 | 2019-02-17 | Bortezomib + Daratumumab | 02 | null | IDELALISIB + RITUXIMAB | 100067689 |
| 10428791 | 10041553 | 1.55 | 76 | Palliative (P) | null | 2018-09-05 | Carboplatin + Paclitaxel + Pembrolizumab | 01 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL + TRASTUZUMAB | 101762478 |
| 10428808 | 10041554 | 1.73 | 68.9 | null | 2017-06-05 | 2017-06-12 | Bortezomib + Daratumumab | 02 | null | FEC | 100456981 |
| 10428829 | 10041555 | 1.79 | 70 | Palliative (P) | 2018-10-06 | 2018-10-06 | MPT | 01 | null | ATEZOLIZUMAB + BEVACIZUMAB | 101416010 |
| 10428836 | 10041556 | 1.56 | 67.2 | Adjuvant (A) | 2009-08-09 | 2019-08-25 | Capecitabine (21days) + Carboplatin | 02 | N | OSIMERTINIB | 101381699 |
| 10428839 | 10041557 | 1.67 | 69.1 | Adjuvant (A) | 2018-12-01 | 2018-12-01 | CHOP R + METHOTREXATE | 02 | N | EOX | 101700664 |
| 10428945 | 10041558 | 1.89 | 56.4 | 03 | 2018-04-09 | 2018-04-09 | CETUXIMAB + RT | 02 | N | CHOP | 100287260 |
| 10429134 | 10041560 | 1.8 | 78.5 | Palliative (P) | 2019-02-05 | 2019-02-06 | ABVD | N | N | AVELUMAB + AXITINIB | 100242224 |